{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:15:22Z","timestamp":1761513322226},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1097\/bpo.0b013e3182a006a0","type":"journal-article","created":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T12:25:11Z","timestamp":1374063911000},"page":"118-122","source":"Crossref","is-referenced-by-count":28,"title":["Musculoskeletal Functional Outcomes in Children With Osteogenesis Imperfecta"],"prefix":"10.1097","volume":"34","author":[{"given":"Ted","family":"Sousa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Bompadre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klane K.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-18-20210227","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta.","volume":"16","author":"Sillence","year":"1979","journal-title":"J Med Genet"},{"key":"R6-18-20210227","first-page":"CD005088","article-title":"Bisphosphonate therapy for osteogenesis imperfecta.","volume":"4","author":"Phillipi","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"R7-18-20210227","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta.","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"key":"R13-18-20210227","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1515\/JPEM.2010.23.1-2.73","article-title":"Cyclic pamidronate therapy in children with osteogenesis imperfecta.","volume":"23","author":"Salehpour","year":"2010","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R14-18-20210227","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1359\/JBMR.051006","article-title":"Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.","volume":"21","author":"DiMeglio","year":"2006","journal-title":"J Bone Miner Res"},{"key":"R15-18-20210227","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/adc.86.5.356","article-title":"Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta.","volume":"86","author":"Astrom","year":"2002","journal-title":"Arch Dis Child"},{"key":"R17-18-20210227","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/01.bpo.0000167079.83835.22","article-title":"Responsiveness and uniqueness of the pediatric outcomes data collection instrument compared to the gross motor function measure for measuring orthopaedic and neurosurgical outcomes in cerebral palsy.","volume":"25","author":"Damiano","year":"2005","journal-title":"J Pediatr Orthop"}],"container-title":["Journal of Pediatric Orthopaedics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BPO.0b013e3182a006a0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:05:03Z","timestamp":1620947103000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01241398-201401000-00018"}},"subtitle":["Associations With Disease Severity and Pamidronate Therapy"],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/bpo.0b013e3182a006a0","relation":{},"ISSN":["0271-6798"],"issn-type":[{"value":"0271-6798","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}